A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma - PubMed
4 hours ago
- #immunotherapy
- #biomarkers
- #melanoma
- Pembrolizumab combined with carboplatin/paclitaxel (CP) was tested in a phase II trial for metastatic melanoma.
- The trial included 30 patients with no prior immunotherapy, assessing safety, efficacy, and immune response correlates.
- 70% of patients completed all 4 CP cycles; 87% continued pembrolizumab for 2 years or until progression.
- Grade 3+ adverse events occurred in 50% of patients, with an ORR of 43% and DCR of 53%.
- Median overall survival was 23.8 months, with better outcomes linked to specific immune cell profiles and lower baseline cytokines.
- Responders had fewer naive CD8 T cells, low CCL3, more mature NK cells, and CD4 T cells expressing BTLA/LAIR-1.
- Lower baseline IL-6, IL-8, and CD4+CD39+ T cells correlated with higher survival rates.
- Pro-inflammatory factors increased post-treatment in both responders and non-responders.
- Combining CP with pembrolizumab showed no clear survival advantage and was less tolerable than pembrolizumab alone.
- Peripheral immune signatures may serve as predictive biomarkers for further investigation.